Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important
- 20 February 2018
- journal article
- review article
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 19 (2) , 145-158
Abstract
Neuroendocrine tumors (NETs) are a group of rare and heterogeneous malignancies that can develop in various organs. A significant number of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is functionally active and presents with symptoms related to the secretion of biologically active substances, leading to the development of distinct clinical syndromes. There are various therapeutic approaches for GEP-NETs, including curative surgery, palliative surgery, local-ablative and loco-regional therapies as well as systemic therapeutic options including peptide receptor radionuclide therapy, cytotoxic therapy, and molecularly targeted therapies. Specific supportive therapy of patients with NETs includes management or prevention of hormone-related clinical syndromes and paraneoplastic states. Supportive therapy plays a key role in NET treatment. Supportive therapy includes debulking surgery and interventional radiologic techniques to reduce tumour bulk or load, as well as systemic medical treatment options to manage or prevent hypersecretion syndromes and treatment-related side effects. Supportive therapies are a type of of comprehensive treatment addressing the patient as a whole person throughout the process of NET treatment. Therefore, supportive therapy also encompasses psychosocial support, expert nursing, nutritional support and management of cancer related pain.Keywords
Funding Information
- China Scholarship Council
This publication has 137 references indexed in Scilit:
- Prognostic Validity of the American Joint Committee on Cancer Staging Classification for Midgut Neuroendocrine TumorsJournal of Clinical Oncology, 2013
- Tryptophan hydroxylase-1 regulates immune tolerance and inflammationJournal of Experimental Medicine, 2012
- Hyperammonemic Encephalopathy in Diffuse Liver Metastasis: Is This the End Stage?Gastroenterology, 2012
- Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related PeptideCase Reports in Oncology, 2012
- Reversing Hyperammonemia in Neuroendocrine TumorsJournal of Clinical Gastroenterology, 2010
- Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)Annals of Oncology, 2010
- Features of Carcinoid Heart Disease Identified by 2- and 3-Dimensional Echocardiography and Cardiac MRICirculation: Cardiovascular Imaging, 2010
- Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumoursAlimentary Pharmacology & Therapeutics, 2009
- Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell linesCancer, 2009
- The Diagnosis and Medical Management of Advanced Neuroendocrine TumorsEndocrine Reviews, 2004